Registry update — unassessed
COVFIS-HOME: A Phase 2 Placebo-Controlled Pilot Study in COVID-19 of Fisetin to Alleviate Dysfunction and Decrease Complications in At-Risk Outpatients
Trial registry update: COMPLETED. Results are posted in the registry; assessment pending.
RCTNotable significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Aug 1, 2023 · Discovered: Sep 16, 2026 · Assessed: — · Historical research backfill
What it does not prove
- The abstract does not report primary outcome results or effect sizes, making it impossible to determine whether fisetin actually reduced complications or by how much.
- Sample size is not reported, preventing assessment of statistical power or reliability of any estimates.
- As a pilot study, findings may not generalize to broader COVID-19 populations or predict efficacy in larger confirmatory trials.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- —
- Primary outcome
- Reduction of complications in COVID-19 patients
- Effect size
- —
- Significance
- Not reported
- Journal
- James L. Kirkland, MD, PhD
- Published
- Aug 1, 2023
Sources
Primary source
- James L. Kirkland, MD, PhD ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
The purpose of this study is to test whether Fisetin, a senolytic drug can assist in the reduction of complications in patients with COVID-19 infection.
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.